Last reviewed · How we verify

Placebo of Gasmotin

Daewoong Pharmaceutical Co. LTD. · Phase 3 active Small molecule

Placebo of Gasmotin is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 3 development for Control arm in clinical trials for Gasmotin (active ingredient: mosapride or similar prokinetic agent).

This is a placebo formulation with no active pharmacological mechanism.

This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in clinical trials for Gasmotin (active ingredient: mosapride or similar prokinetic agent).

At a glance

Generic namePlacebo of Gasmotin
SponsorDaewoong Pharmaceutical Co. LTD.
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 3

Mechanism of action

As a placebo of Gasmotin, this product contains no active ingredient and produces no direct pharmacological effect. It is used as a control in clinical trials to assess the efficacy of the active Gasmotin formulation through comparison of outcomes between treatment and placebo groups.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of Gasmotin

What is Placebo of Gasmotin?

Placebo of Gasmotin is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD., indicated for Control arm in clinical trials for Gasmotin (active ingredient: mosapride or similar prokinetic agent).

How does Placebo of Gasmotin work?

This is a placebo formulation with no active pharmacological mechanism.

What is Placebo of Gasmotin used for?

Placebo of Gasmotin is indicated for Control arm in clinical trials for Gasmotin (active ingredient: mosapride or similar prokinetic agent).

Who makes Placebo of Gasmotin?

Placebo of Gasmotin is developed by Daewoong Pharmaceutical Co. LTD. (see full Daewoong Pharmaceutical Co. LTD. pipeline at /company/daewoong-pharmaceutical-co-ltd).

What development phase is Placebo of Gasmotin in?

Placebo of Gasmotin is in Phase 3.

Related